Press releases
-
-
Internal link ProQR Announces Results for the First Quarter of 2017
-
-
Internal link ProQR Announces R&D Day in New York on June 15
-
-
-
-
Internal link ProQR Announces Annual Meeting of Shareholders
-
Internal link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
-
-
-
Internal link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
-
Internal link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
-
-
Internal link ProQR Announces Results for the Third Quarter of 2016
-
-
-
-
Internal link ProQR Announces Results for the Second Quarter of 2016
-
-
Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
-
Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
-
Internal link ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference
-
Internal link ProQR Announces Results for the First Quarter of 2016
-